<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F</span> literature reference collection</h1>
<div class="effect_section"><h2 id="anthropozoonotic_events">Anthropozoonotic events</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.<br/> (<a href="https://doi.org/10.1101/2021.03.18.436013" class="lit_link">Montagutelli et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07.<br/> B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.<br/> (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistance against most samples, P=0.0020.<br/> (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P=0.0039 for mild resistance.<br/> (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).<br/> (<a href="https://doi.org/10.1101/2021.05.03.442455" class="lit_link">Gallagher et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).<br/> (<a href="https://doi.org/10.1101/2021.04.25.21256049" class="lit_link">Leier et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.013" class="lit_link">Garcia-Beltran et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
